Researchers took aim at mucins, glycoproteins that protect cancer cells from drugs and the immune response, and engineered a revolutionary targeted tool for oncology and beyond.
Researchers employ peripheral blood mononuclear cells (PBMCs) in clinical and academic applications related to the immune system and regenerative medicine.